Bèlgica - anglès - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

noridem enterprises ltd. - caspofungin acetate 77,67 mg - eq. caspofungin 70 mg - powder for concentrate for solution for infusion - 70 mg - caspofungin acetate 77.67 mg - caspofungin

Bèlgica - anglès - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva b.v. - caspofungin acetate 55,52 mg - eq. caspofungin 50 mg - powder for concentrate for solution for infusion - 50 mg - caspofungin acetate 55.52 mg - caspofungin

Bèlgica - anglès - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva b.v. - caspofungin acetate 77,69 mg - eq. caspofungin 70 mg - powder for concentrate for solution for infusion - 70 mg - caspofungin acetate 77.69 mg - caspofungin

Israel - anglès - Ministry of Health

abic marketing ltd, israel - caspofungin as acetate - powder for concentrate for solution for infusion - caspofungin as acetate 50 mg/vial - caspofungin - caspofungin teva is indicated in adults and pediatric patients (3 months and older) for: - empirical therapy for presumed fungal infections in febrile, neutropenic patients. - treatment of candidemia and the following candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. caspofungin teva has not been studied in endocarditis, osteomyelitis, and meningitis due to candida. - treatment of esophageal candidiasis. - treatment of invasive aspergillosis in patients who are refractory to or intolerant to other therapies (i.e. amphotericin b, lipid formulations of amphotericin b, and/or itraconazole). caspofungin teva has not been studied as initial therapy for invasive aspergillosis.

Israel - anglès - Ministry of Health

abic marketing ltd, israel - caspofungin as acetate - powder for concentrate for solution for infusion - caspofungin as acetate 70 mg/vial - caspofungin - caspofungin teva is indicated in adults and pediatric patients (3 months and older) for: - empirical therapy for presumed fungal infections in febrile, neutropenic patients. - treatment of candidemia and the following candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. caspofungin teva has not been studied in endocarditis, osteomyelitis, and meningitis due to candida. - treatment of esophageal candidiasis. - treatment of invasive aspergillosis in patients who are refractory to or intolerant to other therapies (i.e. amphotericin b, lipid formulations of amphotericin b, and/or itraconazole). caspofungin teva has not been studied as initial therapy for invasive aspergillosis.

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

pinewood laboratories ltd - caspofungin - powder for concentrate for solution for infusion - 50 milligram(s) - other antimycotics for systemic use; caspofungin

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

pinewood laboratories ltd - caspofungin - powder for concentrate for solution for infusion - 70 milligram(s) - other antimycotics for systemic use; caspofungin

Estats Units - anglès - NLM (National Library of Medicine)

almaject, inc. - caspofungin acetate (unii: vuw370o5qe) (caspofungin - unii:f0xdi6zl63) - caspofungin acetate for injection is indicated as empirical therapy for presumed fungal infections in febrile, neutropenic adult and pediatric patients (3 months of age and older) [see clinical studies (14.1, 14.5)]. caspofungin acetate for injection is indicated for the treatment of candidemia and the following candida infections: intra-abdominal abscesses, peritonitis, and pleural space infections in adult and pediatric patients (3 months of age and older) [see clinical studies (14.2, 14.5)] . limitations of use : caspofungin acetate for injection has not been studied in endocarditis, osteomyelitis, and meningitis due to candida. caspofungin acetate for injection is indicated for the treatment of esophageal candidiasis in adult and pediatric patients (3 months of age and older) [see clinical studies (14.3, 14.5)] . limitations of use : caspofungin acetate for injection has not been approved for the treatment of oropharyngeal candidiasis (opc). in the study that evaluated the efficacy of caspofungin in the

Israel - anglès - Ministry of Health

propharm ltd - caspofungin as acetate - powder for concentrate for solution for infusion - caspofungin as acetate 50 mg - caspofungin - caspofungin wockhrdt is indicated in adults and pediatric patients (3 months and older) for:- empirical therapy for presumed fungal infections in febrile, neutropenic patients.- treatment of candidemia and the following candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. caspofungin has not been studied in endocarditis, ostemyelitis, and meningitis due to candida.- treatment of esophageal candidiasis.- treatment of invasive aspergillosis in patients who are refractory to or intolerant to other therapies (i.e. amphotericin b, lipid formulations of amphotericin b, and/or itraconazole). caspofungin has not been studied as initial therapy for invasive aspergillosis

Israel - anglès - Ministry of Health

propharm ltd - caspofungin as acetate - powder for concentrate for solution for infusion - caspofungin as acetate 70 mg - caspofungin - caspofungin wockhrdt is indicated in adults and pediatric patients (3 months and older) for:- empirical therapy for presumed fungal infections in febrile, neutropenic patients.- treatment of candidemia and the following candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. caspofungin has not been studied in endocarditis, ostemyelitis, and meningitis due to candida.- treatment of esophageal candidiasis.- treatment of invasive aspergillosis in patients who are refractory to or intolerant to other therapies (i.e. amphotericin b, lipid formulations of amphotericin b, and/or itraconazole). caspofungin has not been studied as initial therapy for invasive aspergillosis